A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME).
Phase of Trial: Phase I/II
Latest Information Update: 27 Jun 2014
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Allergan
- 21 Jan 2013 Results were reported briefly in a Molecular Partners media release.
- 21 Nov 2011 Company Allergan added in associations field as reported by ClinicalTrials.gov.
- 21 Nov 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.